Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma

Max S. Topp, Herbert Eradat, Axel Florschütz, Andreas Hochhaus, Tomasz Wrobel, Jan Walewski, Wanda Knopinska-Posluszny, Abraham S. Kanate, Ewa Lech-Maranda, Uta Brunnberg, Surya Chitra, Tina G. Nielsen, Gila Sellam, Mahesh Shivhare, Izidore S. Lossos

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: New therapies are needed for relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. This phase 1b, open-label trial evaluated two anti-CD20-based triplet combinations. Methods: Patients with R/R follicular lymphoma (FL; n = 13) were treated with obinutuzumab, atezolizumab, and polatuzumab vedotin (G-atezo-pola; 1.4 mg/kg/1.8 mg/kg) and patients with R/R diffuse large B-cell lymphoma (DLBCL; n = 23) received rituximab (R)-atezo-pola. The primary efficacy endpoint was complete response (CR) at end of induction (EOI) by PET-CT (investigator assessed; modified Lugano 2014 criteria). Safety endpoints were also assessed. Results: 13 FL patients were treated and evaluable for safety; 2/23 DLBCL patients did not receive treatment and were not included in the safety population. Median observation time was 23.3 and 5.7 months in the FL and DLBCL cohorts, respectively. At EOI, CR rates in FL patients treated with G-atezo-pola at pola doses of 1.4 mg/kg (N = 3) and 1.8 mg/kg (N = 7) were 33% and 14%, respectively. In DLBCL patients receiving R-atezo-pola, the CR rate at EOI was 13%. In the FL cohort, 62% of patients experienced a grade 3–5 adverse event (AE; including two deaths) and 31% developed a serious AE (SAE). In DLBCL patients, R-atezo-pola was associated with a lower incidence of grade 3–5 AEs (24%; one death) and SAEs (10%). In both cohorts, the most common grade 3–5 AEs were hematologic toxicities. Conclusion: Based on these safety issues, considered as related specifically to G-atezo-pola, and limited efficacy, no further development of either combination is planned. Trial registration: NCT02729896; Date of registration: April 6, 2016.

Original languageEnglish (US)
JournalJournal of cancer research and clinical oncology
DOIs
StateAccepted/In press - 2022
Externally publishedYes

Keywords

  • B-cell non-Hodgkin lymphoma
  • Diffuse large B-cell lymphoma
  • Follicular lymphoma
  • Immunotherapy
  • Relapsed/refractory

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this